In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
FAQs
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
Research and Development Strategies

Defining Biopharma Dealmaking Success: An Analysis Of 2003 Alliances

Executive Summary

This article examines the question do external biopharma programs succeed at similar rates as internal projects? IN VIVO examined this question by analyzing the alliances of 2003, mining both Elsevier's Strategic Transactions database and SEC documents, and bolstering these data with independent reporting.

You may also be interested in...



TransEnterix Names New CFO, Reports Negative Q2 Earnings Amid Challenging Times

TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.

Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

CureVac Launches IPO, Adds To Big 2020 Cash Haul

CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.

Table

View full table

Topics

Related Companies

Related Deals

Tags:
Research and Development Strategies
UsernamePublicRestriction

Register

ID017698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By